German drugmaker Merck said that its experimental cancer medicine evofosfamidehas failed in the last stage of clinical tests due to which it won't seek regulatory approval for its treatment.

On Monday, Darmstadt, Germany-based Merck said in a statement that the medicine wasn’t helpful for patients, having pancreatic cancer or soft-tissue sarcoma live longer when taken along with chemotherapy.

It has been recently announced by drug maker Merck that their drug, which was considered to prevent heart attacks, has been found to be having some serious problems. Due to this, they are going to ask doctors across the world that they should not prescribe the drug anymore.